{
    "clinical_study": {
        "@rank": "60450", 
        "acronym": "REACT", 
        "arm_group": {
            "arm_group_label": "Ranibizumab", 
            "arm_group_type": "Other", 
            "description": "Group A (monthly group) Enrolled subjects will receive multiple open-label intravitreal injections of 0.3 mg ranibizumab administered every 30 days (+/- 7 days from the last treatment) for 12 months in the monthly group."
        }, 
        "brief_summary": {
            "textblock": "The primary objective of the study is to assess the ocular and systemic adverse events of\n      ranibizumab (Lucentis)for DME (diabetic macular edema) following previous treatment with\n      intravitreal bevacizumab (Avastin)."
        }, 
        "brief_title": "Safety and Efficacy of Ranibizumab for Diabetic Macular Edema", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetic Macular Edema", 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Edema"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open-label, Phase I/II study of intravitreally administered 0.3mg ranibizumab\n      (Lucentis) in subjects with DME (diabetic macular edema) previously treated with\n      intravitreal bevacizumab (Avastin) with a randomized comparative dosing strategy, monthly vs\n      \"treat-and-extend.\"   Thirty patients total will be enrolled in the study, 15 in each group.\n       This study will have a 1-year treatment period. The recruitment period will occur over 1\n      year with total potential study duration of 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects will be eligible if the following criteria are met:\n\n               -  Ability to provide written informed consent and comply with study assessments\n                  for the full duration of the study\n\n               -  Age > 18 years\n\n               -  ETDRS best-corrected visual acuity of 20/25 to 20/320 in the study eye\n\n               -  Willing, committed, and able to return for ALL clinic visits and complete all\n                  study related procedures\n\n               -  At least 6 previous bevacizumab injections for diabetic macular edema in the\n                  last 12 months.\n\n               -  At least 2 bevacizumab injections within 10 weeks and the most recent\n                  bevacizumab injection within 6 weeks of baseline study visits\n\n               -  Persistent foveal-involving diabetic macular edema based on presence of\n                  intraretinal and/or subretinal fluid by SDOCT in the foveal center at study\n                  entry\n\n        Exclusion Criteria:\n\n        Subjects who meet any of the following criteria will be excluded from this study:\n\n          -  Pregnancy (positive pregnancy test) or lactation\n\n          -  Premenopausal women not using adequate contraception.  The following are considered\n             effective means of contraception:  surgical sterilization or use of oral\n             contraceptives, barrier contraception with either a condom or diaphragm in\n             conjunction with spermicidal gel, an IUD (intrauterine device), or contraceptive\n             hormone implant or patch.\n\n          -  Intravitreal steroid or periocular steroid treatment within 3 months of study entry\n\n          -  Focal/grid laser photocoagulation treatment within 3 months of study entry\n\n          -  Panretinal photocoagulation treatment within 3 months of study entry\n\n          -  Prior vitrectomy in the study eye\n\n          -  History of retinal detachment in the study eye\n\n          -  Prior trabeculectomy or other filtration surgery in the study eye\n\n          -  Active intraocular inflammation in either eye\n\n          -  Active ocular or periocular infection in either eye\n\n          -  Active scleritis or epicscleritis in either eye\n\n          -  History of any other retinal vascular disease (e.g., retinal vein occlusion, retinal\n             artery occlusion)\n\n          -  Coexistent retinal disease other than diabetic retinopathy (e.g., AMD (age related\n             macular degeneration), inherited retinal disease)\n\n          -  Intraocular surgery within 3 months of study entry.\n\n          -  History of corneal transplant or corneal dystrophy\n\n          -  Significant media opacities in study eye which may interfere with visual acuity\n\n          -  Participation as a subject in any clinical study within 3 months of study entry.\n\n          -  History of allergy to topical iodine"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01982435", 
            "org_study_id": "REACT Study"
        }, 
        "intervention": {
            "arm_group_label": "Ranibizumab", 
            "intervention_name": "Ranibizumab", 
            "intervention_type": "Drug", 
            "other_name": "Lucentis"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Diabetes", 
            "Macular Edema"
        ], 
        "lastchanged_date": "November 4, 2013", 
        "location": {
            "contact": {
                "email": "ehlersj@ccf.org", 
                "last_name": "Justis Ehlers, M.D.", 
                "phone": "216-636-0183"
            }, 
            "contact_backup": {
                "email": "koling@ccf.org", 
                "last_name": "Gail Kolin, BSN RN", 
                "phone": "216-445-4086"
            }, 
            "facility": {
                "address": {
                    "city": "Cleveland", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "44195"
                }, 
                "name": "Cole Eye Institute, Cleveland Clinic"
            }, 
            "investigator": {
                "last_name": "Justis Ehlers, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Safety and Efficacy of Intravitreal Ranibizumab for Diabetic Macular Edema Previously Treated With Intravitreal Bevacizumab: A Randomized Dual Arm Comparative Dosing Trial", 
        "other_outcome": {
            "description": "Best-corrected visual acuity assessed by the number of letters read correctly on the electronic ETDRS (early treatment diabetic retinopathy study) eye chart from baseline to months 6 and 12.", 
            "measure": "Visual Acuity", 
            "safety_issue": "No", 
            "time_frame": "6 and 12 months"
        }, 
        "overall_contact": {
            "email": "ehlersj@ccf.org", 
            "last_name": "Justis Ehlers, M.D.", 
            "phone": "216-636-0183"
        }, 
        "overall_contact_backup": {
            "email": "koling@ccf.org", 
            "last_name": "Gail Kolin, BSN RN", 
            "phone": "216-445-4086"
        }, 
        "overall_official": {
            "affiliation": "The Cleveland Clinic", 
            "last_name": "Justis Ehlers, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Incidence and severity of ocular adverse events, as identified by eye examination (including visual acuity testing) Incidence and severity of other non-ocular adverse events, as identified by physical examination, subject reporting, and changes in vital signs", 
            "measure": "Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "6 and 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01982435"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Central foveal thickness measured by Spectral Domain Optical Coherence Tomography (SDOCT) at 6 and 12 months.", 
            "measure": "Central Foveal Thickness", 
            "safety_issue": "No", 
            "time_frame": "6 and 12 months"
        }, 
        "source": "The Cleveland Clinic", 
        "sponsors": {
            "collaborator": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "The Cleveland Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}